Skip to main
STAA

STAAR Surgical (STAA) Stock Forecast & Price Target

STAAR Surgical (STAA) Analyst Ratings

Based on 8 analyst ratings
Hold
Strong Buy 25%
Buy 13%
Hold 50%
Sell 0%
Strong Sell 13%

Bulls say

Staar Surgical is in a strong position with its focus on a high-demand product, the Implantable Collamer Lens (ICL), which is the only viable surgical option for a significant portion of China's population with myopia. The company's recent record 2Q net sales, continued growth in China, and significant improvement in profitability demonstrates the durability and potential of this market. While the Alcon-related distributor disruptions pose a short-term challenge, the leadership transition from interim Co-CEOs to permanent CEO Warren Foust is a positive development, and the company's strong financial position with no debt and a cash balance over $200M provides flexibility for strategic options.

Bears say

Staar Surgical is heavily reliant on the sales of its ICL products, which constitute almost all of its revenue, and the recent US approval for ICL patient eligibility at age 60 is a notable expansion. However, competition in the phakic lens market is intensifying with other companies pursuing R&D in broader power ranges and lens sizing. Furthermore, the unpredictable near-term seasonality patterns in China pose a risk to Staar's performance and its ability to compete with the dominance of LASIK procedures in the market.

STAAR Surgical (STAA) has been analyzed by 8 analysts, with a consensus rating of Hold. 25% of analysts recommend a Strong Buy, 13% recommend Buy, 50% suggest Holding, 0% advise Selling, and 13% predict a Strong Sell.

This aggregate rating is based on analysts' research of STAAR Surgical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About STAAR Surgical (STAA) Forecast

Analysts have given STAAR Surgical (STAA) a Hold based on their latest research and market trends.

According to 8 analysts, STAAR Surgical (STAA) has a Hold consensus rating as of Aug 21, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $27.81, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $27.81, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

STAAR Surgical (STAA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.